2[1]Ganz PA, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and chemotherapy in metastatic nonsmall cell lung cancer: Doses chemotherapy make a difference?[J]. Cancer, 1998 ;6(1): 1271 - 1278.
3[3]Pasquini E, Tassinari D, Niconlini M, et al. Gemcitabine in advanced NSCLC of elderly:A phase Ⅱ study[J]. Ann Oncol,1998 ;4(suppl): A154 - 157.
4[4]Klastersky J, Sculier JP. Dose - finding study of paclitaxel plus cisplatin in patients with non- small cell lung cancer[J].Lung Cancer, 1995; 12(suppl): 117 - 125.
5Souquet PJ, Tan EH, Rodrigues Pereira J, et al. GLOB-1: a prospective randomised clinical phase Ⅲ trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-smallcell lung cancer patients. Ann Oncol,2002,13(12) : 1853-1
6Shepherd FA. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol, 1999,26(1 Suppl 4) : 3-11.
7Giaccone G. State of the art in systemic treatment of lung cancer.Eur J Cancer,2001,37(Suppl 7): S99-S114.
8Pirker R. Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer. Lung Cancer,2002,38(Suppi 3): S53-S55.
9Rey F, Astoul P, Marqueste L, et al. Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage Ⅲ-Ⅳ non-small-cell lung cancer: a phase Ⅱ study. Am J Clin Onco1,1998,21(5): 518-522.
10Chen YR,Liao ML,Xiong LW,et al. Vinorelbine combined chemotherapy in stageⅢnon-small cell lung cancer.J Prac Oncol,2000,15(6):422-423.[陈玉蓉,廖美琳,熊丽文,等.长春瑞宾为主的联合化疗诱导治疗Ⅲ期非小细胞肺癌.实用肿瘤杂志,
